Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8304218 | 1.00 | CYP3A4 (0.57) | CYP3A4KDM4EALDH1A1KMT2AFKBP1A | |
| SCHEMBL8304214 | 1.00 | CYP3A4 (0.57) | CYP3A4KDM4EALDH1A1KMT2AFKBP1A | |
| SCHEMBL8304211 | 1.00 | CYP3A4 (0.57) | CYP3A4KDM4EALDH1A1KMT2AFKBP1A | |
| SCHEMBL5458626 | 0.95 | CYP3A4 (0.54) | CYP3A4KDM4EALDH1A1KMT2AFKBP1A | |
| SCHEMBL5451605 | 0.95 | CYP3A4 (0.54) | CYP3A4KDM4EALDH1A1KMT2AFKBP1A | |
| SCHEMBL9352245 | 0.95 | CYP3A4 (0.54) | CYP3A4KDM4EALDH1A1KMT2AFKBP1A | |
| SCHEMBL9352229 | 0.92 | KMT2A (0.55) | CYP3A4KDM4EALDH1A1KMT2AFKBP1A | |
| SCHEMBL15406170 | 0.90 | FKBP1A (0.56) | CYP3A4KDM4EALDH1A1KMT2AFKBP1A | |
| SCHEMBL5965409 | 0.90 | FKBP1A (0.56) | CYP3A4KDM4EALDH1A1KMT2AFKBP1A | |
| SCHEMBL6684412 | 0.89 | CYP3A4 (0.54) | CYP3A4KDM4EALDH1A1KMT2AFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649244-B2 | Method for synthesizing diaza-bridged compound and a diaza-bridged compound | LinkChem Co., Ltd., Shanghai (CN) | 2023-05-16 | — | — | US | disclosed |
| US-20070225492-A1 | 3,6-Diazabicyclo[3.1.1]Heptane Derivatives with Analgesic Activity | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2007-09-27 | — | — | US | disclosed |
| US-20070225492-A1 | 3,6-Diazabicyclo[3.1.1]Heptane Derivatives with Analgesic Activity | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2007-09-27 | — | — | US | disclosed |
| EP-0299513-B1 | Azetidine derivatives, compositions and their use | FIDIA GEORGETOWN INST (US) | 1994-10-05 | — | — | EP | disclosed |
| US-4990504-A | Modulate excitatory amino acid receptor system | FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1991-02-05 | — | — | US | disclosed |
| US-4946839-A | ALZHEIMER'S DISEASE | FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1990-08-07 | — | — | US | disclosed |
| EP-0299513-A1 | Azetidine derivatives, compositions and their use | FIDIA-GEORGETOWN INSTITUTE FOR THE NEUROSCIENCES (US) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225492-A1 | 3,6-Diazabicyclo[3.1.1]Heptane Derivatives with Analgesic Activity | OPRK1, OPRM1, OPRD1 | CYP3A4 148/4885KDM4E 3414/4885ALDH1A1 94/4885 |
| US-11649244-B2 | Method for synthesizing diaza-bridged compound and a diaza-bridged compound | DGAT2, NOS2, ABL1 | CYP3A4 1148/4885KDM4E 2616/4885ALDH1A1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.